MARC Record from marc_columbia

LEADER: 05825cam a2200673 i 4500
001 15274983
005 20220703234547.0
006 m o d
007 cr cnu---unuuu
008 201211s2021 flua ob 001 0 eng
035 $a(OCoLC)on1227044579
035 $a(NNC)15274983
040 $aAU@$beng$erda$epn$cAU@$dOCLCO$dYDXIT$dTYFRS$dOCLCF$dTYFRS$dOCLCQ$dOCLCO$dOCLCA$dN$T$dOCLCO
020 $a9781351013154$q(electronic book bk.)
020 $a1351013157$q(electronic book bk.)
020 $a1351013130$q(electronic bk. ;$qEPUB)
020 $a9781351013147$q(electronic bk. ;$qPDF)
020 $a1351013149$q(electronic bk. ;$qPDF)
020 $a9781351013123$q(electronic bk. ;$qMobipocket)
020 $a1351013122$q(electronic bk. ;$qMobipocket)
020 $a9781351013130$q(electronic bk.)
020 $z9780815347774
020 $z0815347774
035 $a(OCoLC)1227044579
037 $a9781351013154$bTaylor & Francis
050 4 $aRM301.4$b.B44 2021
060 4 $aQV 241
072 7 $aMED$x008000$2bisacsh
072 7 $aMED$x071000$2bisacsh
072 7 $aTDCW$2bicssc
082 04 $a615.7$223
049 $aZCUA
100 1 $aBehera, Basanta Kumara,$eauthor.
245 10 $aBiopharmaceuticals :$bchallenges and opportunities /$cauthored by Basanta Kumara Behera.
264 1 $aBoca Raton :$bCRC Press,$c2021.
300 $a1 online resource :$billustrations
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
504 $aIncludes bibliographical references and index.
505 0 $aBiopharmaceutical : A New Confront -- Biopharmaceutical Production -- Transitioning from Pharmaceutical to Biopharmaceutical -- Biopharmaceutical from Animal cells -- Plant Biomolecules and Therapeutic -- Biosimilar -- Biopharmaceutical Supply Chain Management.
520 $a"This book highlights how traditional microbial process technology has been upgraded for the production of biologic drugs, and evolution of manufacturing process to meet the global market demand with quality products under the guide lines of internally recognised regulatory bodies. This piece of work also carries information on how armed with deeper understanding of life threatening disease, the biopharmaceutical companies or life sciences industries have developed royal scientific heritage of understanding by developing formal and informal partnerships with researchers in institute, universities and other R & D organisation to fulfil the promise of timely quality production with perfect safety and security. One of the most interesting aspects of this piece of work is the conceptual development of personalized medicine (or precision medicine) to get the right treatment to the right patient at the right dose at the earlier stage of development of any inherited disease. Besides this, it also high lights on the most challenging aspects of modern biopharmaceutical science focusing on the most burning topics like design and development of biologic drugs; use of diversified groups of host cells belonging from animals, plants, microbes, insects and mammals; stem cell therapy and gene therapy; supply chain management of biopharmaceuticals; and the future scope of biopharmaceutical industry development. This book is a latest resource for a wide circle of scientists, students and researchers involve in understanding and implementing the knowledge of biopharmaceutical to develop biologics for life saving drugs, and bring awareness on personalized medicines that can potentially offer patients faster diagnoses, fewer side effects and better outcomes. Features: Explains how the traditional cells culture methodology has been changed to fully continuous or partially continuous process. It explains how to design and fabricate living organs of body by 3D bioprinting technology. It focuses on how a biopharmaceutical company confront with various problems of regulatory bodies, and develop innovative biologic drugs. It narrates in detail the update information on stem cell therapy and gene therapy. It explains the development strategies and clinical significance of bio-similars and bio-betters. It high lights on supply chain management of biopharmaceuticals"-
545 0 $aDr. Basanta Kumara Behera served as professor and director of biotechnology at three distinguished Indian universities, where he had been regularly associated with teaching and research at post graduate level courses on the topic related to Microbial processing technology, fermentation technology, biotechnology, genetic engineering, protein engineering, and therapeutic proteins. In 2009 he joined a MNS company as adviser for speciality chemicals production and drug design through microbial process technology. Prof. Behera is associated with national and international repute companies as technical adviser for the production of biopharmaceuticals under cGMP norms. Dr Behera has credit of being authored books published/in Springer Verlag, Germany; Elsevier USA; CABI, UK.
650 0 $aPharmaceutical biotechnology.
650 0 $aBiopharmaceutics.
650 12 $aBiological Products
650 22 $aBiopharmaceutics
650 22 $aDrug Industry$xtrends
650 6 $aBiotechnologie pharmaceutique.
650 6 $aBiopharmacie.
650 7 $aMEDICAL$xBiochemistry.$2bisacsh
650 7 $aMEDICAL$xPharmacology.$2bisacsh
650 7 $aBiopharmaceutics.$2fast$0(OCoLC)fst00832650
650 7 $aPharmaceutical biotechnology.$2fast$0(OCoLC)fst01060106
655 4 $aElectronic books.
776 08 $iPrint version:$z9781351013130
776 08 $iPrint version:$z9780815347774$z0815347774$w(DLC) 2020033145
856 40 $uhttp://www.columbia.edu/cgi-bin/cul/resolve?clio15274983$zTaylor & Francis eBooks
852 8 $blweb$hEBOOKS